A Randomized, Phase 3, Open-label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 <50%

Trial Profile

A Randomized, Phase 3, Open-label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 <50%

Recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Mar 2018

At a glance

  • Drugs Cemiplimab (Primary) ; Ipilimumab
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 12 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 07 Feb 2018 According to a Sanofi media release, company plans to initiate this study in Q1 2018.
    • 23 Jan 2018 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top